Understanding Statin‐Roxadustat Drug–Drug‐Disease Interaction Using Physiologically‐Based Pharmacokinetic Modeling
Open Access
- 13 July 2023
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (4) , 825-835
Abstract
A different drug–drug interaction (DDI) scenario may exist in patients with chronic kidney disease (CKD) compared with healthy volunteers (HVs), depending on the interplay between drug–drug and disease (drug‐drug‐disease interaction (DDDI)). Physiologically‐based pharmacokinetic (PBPK) modeling, in lieu of a clinical trial, is a promising tool for evaluating these complex DDDIs in patients. However, the prediction confidence of PBPK modeling in the severe CKD population is still low when nonrenal pathways are involved. More mechanistic virtual disease population and robust validation cases are needed. To this end, we aimed to: (i) understand the implications of severe CKD on statins (atorvastatin, simvastatin, and rosuvastatin) pharmacokinetics (PK) and DDI; and (ii) predict untested clinical scenarios of statin‐roxadustat DDI risks in patients to guide suitable dose regimens. A novel virtual severe CKD population was developed incorporating the disease effect on both renal and nonrenal pathways. Drug and disease PBPK models underwent a four‐way validation. The verified PBPK models successfully predicted the altered PKs in patients for substrates and inhibitors and recovered the observed statin‐rifampicin DDIs in patients and the statin‐roxadustat DDIs in HVs within 1.25‐ and 2‐fold error. Further sensitivity analysis revealed that the severe CKD effect on statins PK is mainly mediated by hepatic BCRP for rosuvastatin and OATP1B1/3 for atorvastatin. The magnitude of statin‐roxadustat DDI in patients with severe CKD was predicted to be similar to that in HVs. PBPK‐guided suitable dose regimens were identified to minimize the risk of side effects or therapeutic failure of statins when co‐administered with roxadustat.Keywords
Funding Information
- AstraZeneca
This publication has 38 references indexed in Scilit:
- Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPKCPT: Pharmacometrics & Systems Pharmacology, 2015
- Physiologically Based Models in Regulatory Submissions: Output From the ABPI/MHRA Forum on Physiologically Based Modeling and SimulationCPT: Pharmacometrics & Systems Pharmacology, 2015
- Quantitative Profiling of Human Renal UDP-glucuronosyltransferases and Glucuronidation Activity: A Comparison of Normal and Tumoral Kidney TissuesDrug Metabolism and Disposition, 2015
- Dealing with the complex drug–drug interactions: Towards mechanistic modelsBiopharmaceutics & Drug Disposition, 2015
- Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney diseaseClinical and Experimental Nephrology, 2013
- Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1Clinical Pharmacology & Therapeutics, 2012
- Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practiceBiopharmaceutics & Drug Disposition, 2012
- Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysisThe Lancet, 2010
- Gender Differences in mRNA Expression of ATP-Binding Cassette Efflux and Bile Acid Transporters in Kidney, Liver, and Intestine of 5/6 Nephrectomized RatsDrug Metabolism and Disposition, 2008
- Drug protein binding in chronic renal failure: Evaluation of nine drugsKidney International, 1988